Ileocolonic-Targeted JAK Inhibitor: A Safer and More Effective Treatment for Inflammatory Bowel Disease

Ileocolonic-Targeted JAK Inhibitor: A Safer and More Effective Treatment for Inflammatory Bowel Disease

Janus kinase (JAK) inhibitors, such as tofacitinib (Xeljanz) and filgotinib (Jyseleca), have been approved for treatment of ulcerative colitis with several other JAK inhibitors in late-stage clinical trials for inflammatory bowel disease (IBD). Despite their impressive efficacy, the risk of adverse...

Full description

Bibliographic Details
Main Authors: Vipul Yadav, Aileen House, Silvia Matiz, Laura E. McCoubrey, Kimberly A. Bettano, Leena Bhave, Meiyao Wang, Peter Fan, Siqun Zhou, Janice D. Woodhouse, Eirini Poimenidou, Liu Dou, Abdul W. Basit, Lily Y. Moy, Robert Saklatvala, Laxminarayan G. Hegde, Hongshi Yu
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Pharmaceutics
Subjects:
JAK inhibitors
colonic drug delivery
drug stability
ulcerative colitis
Crohn’s disease
anti-inflammatory
Online Access:https://www.mdpi.com/1999-4923/14/11/2385

Similar Items

Similar Items